Online inquiry

IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6210MR)

This product GTTS-WQ6210MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets RABVgp4 gene. The antibody can be applied in Rabies research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NP_056796.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1489856
UniProt ID P08667
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6210MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8100MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ11057MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ3652MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ9046MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ3783MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ3690MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ5701MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ13464MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRS-343
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW